Evaluating a novel cardioprotective agent against DOX-induced cardiotoxicity in transgenic zebrafish model
Doxorubicin (DOX) is an anticancer drug which has been widely used and become one of the most prescribed antineoplastic agent due to its high efficacy in fighting a wide array of cancers. However, its usage is greatly limited by its well-known side effect, cardiotoxicity. DOX-induced cardiotoxicity...
| Päätekijä: | |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Final Year Project (FYP) |
| Kieli: | English |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | http://hdl.handle.net/10356/64757 |